Grufity logoGrufity logo

Verve Therapeutics Inc Stock Research

VERV

14.42USD+0.07(+0.49%)Delayed

Market Summary

USD14.42+0.07
Delayed
0.49%

VERV Stock Price

VERV RSI Chart

VERV Valuation

Market Cap

890.2M

Price/Earnings (Trailing)

-5.66

Price/Sales (Trailing)

458.61

Price/Free Cashflow

-6.57

VERV Price/Sales (Trailing)

VERV Profitability

Return on Equity

-28.57%

Return on Assets

-23.17%

Free Cashflow Yield

-15.23%

VERV Fundamentals

VERV Revenue

Revenue (TTM)

1.9M

VERV Earnings

Earnings (TTM)

-157.4M

Earnings Y/Y

-31.11%

Earnings Q/Q

9.08%

Price Action

52 Week Range

10.7043.00
(Low)(High)

Last 7 days

-14.8%

Last 30 days

-27.9%

Last 90 days

-20.8%

Trailing 12 Months

-40.0%

VERV Financial Health

Current Ratio

16.05

VERV Investor Care

Shares Dilution (1Y)

27.25%

Diluted EPS (TTM)

-2.91

Financials for Verve Therapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32021Q42020Q4
Revenue-47.8%1,941,0003,716,000-
Operating Expenses10.7%167,628,000151,446,00087,067,000--
  S&GA Expenses14.8%37,533,00032,695,00018,865,000--
  R&D Expenses9.6%130,095,000118,751,00068,202,000--
Net Income-6.6%-157,387,000-147,639,000-120,314,000--
Net Income Margin-104.1%-81.09-39.73---
Free Cahsflow-7.0%-135,564,000-126,728,000---
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets0.9%679673324349384
  Current Assets0.3%563562299329367
    Cash Equivalents-56.6%12027773.0091.0064.00
  Net PPE23.9%19.0015.0012.0011.007.00
Liabilities2.3%12812528.0018.0027.00
  Current Liabilities20.9%35.0029.0026.0015.0022.00
Shareholder's Equity0.5%551548296331357
  Retained Earnings-13.6%-344-303-257-217-186
  Additional Paid-In Capital5.1%896852555549544
Accumulated Depreciation20.5%4.003.003.002.00-
Shares Outstanding2.1%62.0060.0049.0049.0049.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-4.1%-122-117-109-96.25-77.88
  Share Based Compensation21.3%22.0019.0015.0011.007.00
Cashflow From Investing-249.5%-155-44.63-201-190-239
Cashflow From Financing13.2%3292911.00284377

Risks for VERV

What is the probability of a big loss on VERV?

85.0%


Probability that Verve Therapeutics stock will be more than 20% underwater in next one year

85.0%


Probability that Verve Therapeutics stock will be more than 30% underwater in next one year.

82.8%


Probability that Verve Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VERV drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Verve Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for VERV

Cumulative Returns on VERV

Which funds bought or sold VERV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-02-28
Voya Investment Management LLC
added
3.45
-248,919
347,081
-%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
new
-
77.00
77.00
-%
2023-02-16
HARBOUR INVESTMENTS, INC.
new
-
19,350
19,350
-%
2023-02-15
MetLife Investment Management, LLC
unchanged
-
-370,500
477,500
-%
2023-02-15
JANE STREET GROUP, LLC
new
-
267,340
267,340
-%
2023-02-15
McIlrath & Eck, LLC
unchanged
-
-1,549
1,451
-%
2023-02-15
LAZARD ASSET MANAGEMENT LLC
reduced
-21.5
-37,000
27,000
-%
2023-02-15
NOMURA HOLDINGS INC
new
-
634,000
634,000
-%
2023-02-15
Metropolitan Life Insurance Co/NY
unchanged
-
-41,859
54,141
-%
2023-02-15
Highlander Capital Management, LLC
unchanged
-
-7,000
10,000
-%

1–10 of 45

Latest Funds Activity

Are funds buying VERV calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own VERV
No. of Funds

Verve Therapeutics News

Defense World

Analysts Set Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target ....

Defense World,
11 hours ago

Beaumont Enterprise

Verve Therapeutics: Q4 Earnings Snapshot.

Beaumont Enterprise,
24 days ago

The Motley Fool

GuruFocus.com

The Motley Fool

Schedule 13G FIlings of Verve Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
singer james r
8.1%
5e+06
SC 13G/A
Feb 14, 2023
casdin capital, llc
3.7%
2,290,571
SC 13G/A
Feb 13, 2023
arch venture fund x, l.p.
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
6.19%
3,812,024
SC 13G
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 07, 2023
state street corp
7.26%
4,471,049
SC 13G
Feb 06, 2023
wellington management group llp
1.39%
859,102
SC 13G/A
Feb 14, 2022
gv 2017, l.p.
13.12%
6,320,905
SC 13G
Feb 14, 2022
casdin capital, llc
6.5%
3,138,167
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A

VERV Fair Value

Recent SEC filings of Verve Therapeutics

View All Filings
Date Filed Form Type Document
Mar 02, 2023
10-K
Annual Report
Mar 02, 2023
8-K
Current Report
Mar 02, 2023
S-8
Employee Benefits Plan
Feb 23, 2023
3
Insider Trading
Feb 17, 2023
8-K
Current Report
Feb 16, 2023
4
Insider Trading
Feb 16, 2023
4
Insider Trading
Feb 16, 2023
4
Insider Trading
Feb 16, 2023
4
Insider Trading
Feb 16, 2023
4
Insider Trading

Latest Insider Trading transactions for VERV

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-12-14
Bellinger Andrew
acquired
103,320
2.87
36,000
cso & cmo
2022-12-01
Bellinger Andrew
sold
-19,851
22.95
-865
cso & cmo
2022-11-29
Dorval Allison
acquired
-
-
1,875
chief financial officer
2022-11-29
Dorval Allison
sold
-12,243
22.1
-554
chief financial officer
2022-11-04
GV 2017 GP, L.L.C.
sold
-1,512,810
31.1386
-48,583
-
2022-11-04
Yeshwant Krishna
sold
-1,512,810
31.1386
-48,583
-
2022-11-04
Yeshwant Krishna
sold
-
-
-48,583
-
2022-11-04
GV 2017 GP, L.L.C.
sold
-1,512,800
31.1386
-48,583
-
2022-11-04
GV 2017 GP, L.L.C.
sold
-
-
-48,583
-
2022-11-03
GV 2017 GP, L.L.C.
sold
-
-
-49,569
-

1–10 of 50

Sekar Kathiresan
110
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

VERV Income Statement

2022-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Collaborations revenue$ 1,941$ 0$ 0
Operating expenses:   
Research and development130,09568,20235,371
General and administrative37,53318,8655,256
Total operating expenses167,62887,06740,627
Loss from operations(165,687)(87,067)(40,627)
Other income (expense):   
Change in fair value of preferred stock tranche liability002,507
Change in fair value of antidilution rights liability0(25,574)(5,359)
Change in fair value of success payment liability1,486(7,815)(2,387)
Interest and other income, net6,867142162
Total other expense, net8,353(33,247)(5,077)
Loss before provision for income taxes(157,334)(120,314)(45,704)
Provision for income taxes5300
Net loss$ (157,387)$ (120,314)$ (45,704)
Net loss per common share attributable to common stockholders, basic$ (2.91)$ (4.48)$ (20.31)
Net loss per common share attributable to common stockholders, diluted$ (2.91)$ (4.48)$ (20.31)
Weighted-average common shares used in net loss per share attributable to common stockholders, basic54,023,65326,872,0362,250,093
Weighted-average common shares used in net loss per share attributable to common stockholders, diluted54,023,65326,872,0362,250,093
Comprehensive Loss:   
Net loss$ (157,387)$ (120,314)$ (45,704)
Other comprehensive loss:   
Unrealized loss on marketable securities(466)(236)(1)
Comprehensive loss$ (157,853)$ (120,550)$ (45,705)

VERV Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 115,412$ 64,330
Marketable securities439,396296,112
Collaboration receivable1,0120
Prepaid expenses and other current assets7,3396,686
Total current assets563,159367,128
Property and equipment, net18,7787,224
Restricted cash4,8245,237
Operating lease right-of-use assets91,8771,839
Other long term assets5852,696
Total assets679,223384,124
Current liabilities:  
Accounts payable2,4247,077
Accrued expenses20,76712,992
Operating lease obligations, current portion11,9041,955
Total current liabilities35,09522,024
Long-term lease liability70,0140
Deferred revenue, non-current20,014
Success payment liability2,8854,371
Other long term liabilities283377
Total liabilities128,29126,772
Commitments and contingencies (See Note 7 and 8)
Convertible preferred stock (See Note 10)00
Stockholders’ equtiy (deficit):  
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and oustanding00
Common stock, $0.001 par value; 200,000,000 and 255,000,000 shares authorized at December 31, 2022 and 2021, respectively, 61,730,816 and 48,511,735 shares issued at December 31, 2022 and 2021, respectively; 61,730,816 and 48,511,735 shares outstanding at December 31, 2022 and 2021, respectively6249
Additional paid-in capital895,801544,381
Accumulated other comprehensive (loss) income(694)(228)
Accumulated deficit(344,237)(186,850)
Total stockholders’ equity (deficit)550,932357,352
Total liabilities, and stockholders' equity$ 679,223$ 384,124